The days when drug makers could easily sign deals with front-running antibody developers are over, ended by acquisitions and exclusive arrangements for the most desirable targets. arGEN-X BV believes this is but one dynamic that will attract partners to its therapeutic antibody platform, which entails active immunization of llamas. To flaunt the diversity and potency of its "camelid" antibodies, ArGEN-X aims to raise antibodies to traditionally tough targets, such as membrane-bound proteins like GPCRs.
Dr. Molewaterplein 50
3015 GE Rotterdam, Netherlands
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.
Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.
The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.
